Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Peer-reviewed research, clinical studies, and scientific papers related to eFlow® Technology and inhaled therapies.
Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS.
Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.
Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.
Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.